Health & Fitness
Wed, November 2, 2011Tue, November 1, 2011Mon, October 31, 2011Sat, October 29, 2011Fri, October 28, 2011Thu, October 27, 2011Wed, October 26, 2011Tue, October 25, 2011Mon, October 24, 2011Sat, October 22, 2011Fri, October 21, 2011Thu, October 20, 2011Wed, October 19, 2011Tue, October 18, 2011Mon, October 17, 2011Anthera Announces Third Quarter 2011 Financial Report and Conference Call
//health-fitness.news-articles.net/content/2011/ .. r-2011-financial-report-and-conference-call.html
Published in Health and Fitness on Monday, October 24th 2011 at 19:03 GMT by Market WireAnthera Announces Third Quarter 2011 Financial Report and Conference Call -- HAYWARD, Calif., Oct. 24, 2011 /PRNewswire/ --
Anthera Announces Third Quarter 2011 Financial Report and Conference Call
HAYWARD, Calif., Oct. 24, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: [ ANTH ]), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it will release its third quarter 2011 financial report and provide an update on its development programs after market close on Tuesday, November 1, 2011. Anthera will host a conference call at 5 pm Eastern Time in conjunction with the release.
Conference Call Access: | ||
Date: | November 1, 2011 | |
Time: | 5:00 pm Eastern Time | |
Domestic Dial-in: | (877) 312-8807 | |
International Dial-in: | (253) 237-1190 | |
Conference ID: | 22066672 | |
To access the 24-hour audio replay, U.S. and Canadian participants may dial (855) 859-2056; international participants may dial (404) 537-3406. The conference ID for the replay is 22066672. The audio replay will be available until November 8, 2011.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has three late stage clinical products: varespladib methyl (A-002), A-001 and blisibimod (A-623). Varespladib methyl (A-002) and A-001 are designed to inhibit a novel enzyme target known as secretory phospholipase A2 (sPLA2). Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. Blisibimod targets elevated levels of B-lymphocyte stimulator (BAFF), which have been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus (lupus) and rheumatoid arthritis.
CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., [ bnery@anthera.com ] or 510-856-5586.
SOURCE Anthera Pharmaceuticals, Inc.
[ Back to top ] RELATED LINKS
[ http://www.anthera.com ]
